Francesca Spada

2.9k total citations
113 papers, 1.6k citations indexed

About

Francesca Spada is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Francesca Spada has authored 113 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Oncology, 80 papers in Epidemiology and 52 papers in Neurology. Recurrent topics in Francesca Spada's work include Neuroendocrine Tumor Research Advances (78 papers), Lung Cancer Research Studies (69 papers) and Neuroblastoma Research and Treatments (50 papers). Francesca Spada is often cited by papers focused on Neuroendocrine Tumor Research Advances (78 papers), Lung Cancer Research Studies (69 papers) and Neuroblastoma Research and Treatments (50 papers). Francesca Spada collaborates with scholars based in Italy, United States and France. Francesca Spada's co-authors include Nicola Fazio, Jean Squifflet, Michelle Nisolle, Jacques Donnez, Chiara Alessandra Cella, Massimo Barberis, Salvatore Galdy, Eleonora Pisa, Emilio Bertani and Monica Giovannini and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Francesca Spada

104 papers receiving 1.6k citations

Peers

Francesca Spada
M K Heatley United Kingdom
Orla McArdle Ireland
Gordon Stamp United Kingdom
Francesca Spada
Citations per year, relative to Francesca Spada Francesca Spada (= 1×) peers Alessandro Mangogna

Countries citing papers authored by Francesca Spada

Since Specialization
Citations

This map shows the geographic impact of Francesca Spada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Spada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Spada more than expected).

Fields of papers citing papers by Francesca Spada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesca Spada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Spada. The network helps show where Francesca Spada may publish in the future.

Co-authorship network of co-authors of Francesca Spada

This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Spada. A scholar is included among the top collaborators of Francesca Spada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Spada. Francesca Spada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grignani, Giovanni, Piotr Rutkowski, Célèste Lebbé, et al.. (2025). Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201). Journal for ImmunoTherapy of Cancer. 13(8). e012478–e012478. 2 indexed citations
2.
Ravizza, D., Vincenzo Bagnardi, Cristina Trovato, et al.. (2024). Gastric neuroendocrine tumors: 20‐Year experience in a reference center. Journal of Neuroendocrinology. 36(12). e13440–e13440. 3 indexed citations
3.
Gervaso, Lorenzo, Gianmaria Frigè, Francesca Spada, et al.. (2024). The Role of Liquid Biopsy in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers. 16(19). 3349–3349. 2 indexed citations
4.
Gervaso, Lorenzo, Aurora Gaeta, Sara Gandini, et al.. (2024). Venous thromboembolism in pancreatic neuroendocrine neoplasm: a cohort study. Research and Practice in Thrombosis and Haemostasis. 8(3). 102381–102381. 1 indexed citations
5.
Mortier, Laurent, Lisa Villabona, Ben Lawrence, et al.. (2024). Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study. American Journal of Clinical Dermatology. 25(6). 987–996. 3 indexed citations
6.
Grignani, Giovanni, Piotr Rutkowski, Célèste Lebbé, et al.. (2023). 1146P Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC). Annals of Oncology. 34. S686–S686. 10 indexed citations
7.
Salvia, Anna La, Jaume Capdevila, Marta Benavent, et al.. (2023). Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival. European Journal of Endocrinology. 190(1). 62–74. 6 indexed citations
8.
Cella, Chiara Alessandra, Riccardo Cazzoli, Nicola Fazio, et al.. (2023). Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms. Endocrine Related Cancer. 30(12). 2 indexed citations
9.
Spada, Francesca, Paolo Bossi, Corrado Caracò, et al.. (2022). Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. Journal for ImmunoTherapy of Cancer. 10(6). e004742–e004742. 6 indexed citations
10.
Spada, Francesca, Samuele Frassoni, Vincenzo Bagnardi, et al.. (2022). Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single‐center retrospective analysis. Journal of Neuroendocrinology. 34(10). e13189–e13189. 1 indexed citations
11.
Ferollà, Piero, Alfredo Berruti, Francesca Spada, et al.. (2022). Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. Neuroendocrinology. 113(3). 332–342. 16 indexed citations
12.
Telalović, Jasminka Hasić, Serena Pillozzi, Daniele Lavacchi, et al.. (2021). A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. Diagnostics. 11(5). 804–804. 6 indexed citations
13.
Bertani, Emilio, F. Collamati, Marzia Colandrea, et al.. (2021). First Ex Vivo Results of β -Radioguided Surgery in Small Intestine Neuroendocrine Tumors with 90 Y-DOTATOC. Cancer Biotherapy and Radiopharmaceuticals. 36(5). 397–406. 7 indexed citations
14.
Zerini, Dario, Francesca Spada, Nicola Fazio, et al.. (2020). Multidisciplinary team approach for Merkel cell carcinoma: the European Institute of Oncology experience with focus on radiotherapy. Tumori Journal. 107(2). 145–149. 5 indexed citations
15.
Buonomo, Barbara, et al.. (2020). Discussing motherhood when the oncological prognosis is dire: ethical considerations for physicians. ESMO Open. 5(6). e000956–e000956. 4 indexed citations
16.
Ferollà, Piero, Alfredo Berruti, Francesca Spada, et al.. (2020). 1161MO Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results. Annals of Oncology. 31. S773–S773. 9 indexed citations
17.
Spada, Francesca, Nicola Fazio, Guido Bonomo, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 6. 280–280. 4 indexed citations
18.
Divari, Sara, Francesca Tiziana Cannizzo, Raffaella De Maria, et al.. (2012). Application of absolute qPCR as a screening method to detect illicit 17β-oestradiol administration in male cattle. Food Additives & Contaminants Part A. 30(2). 253–263. 5 indexed citations
19.
Divari, Sara, Raffaella De Maria, Francesca Tiziana Cannizzo, et al.. (2009). A RIKILT yeast estrogen bioassay (REA) for estrogen residue detection in urine of calves experimentally treated with 17β-estradiol. Food Additives & Contaminants Part A. 27(1). 19–28. 11 indexed citations
20.
Donnez, Jacques, Francesca Spada, Jean Squifflet, & Michelle Nisolle. (2000). Bladder endometriosis must be considered as bladder adenomyosis. Fertility and Sterility. 74(6). 1175–1181. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026